Clinical Trials

Phase 2/3 Not yet recruiting

Neoplasm Metastasis, Colorectal Neoplasms

NCT07437287 2026-02-27

CROCOBIL

160 enrolled

Biliary Tract Neoplasms

NCT07432568 2026-02-25

A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

30 enrolled

Phase 1 Not yet recruiting

Cholangiocarcinoma

NCT07363408 2026-01-23

Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer

30 enrolled

Colorectal Neoplasms

NCT07353827 2026-01-20

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

36 enrolled

Phase 4 Not yet recruiting

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT07094893 2026-01-14

ARIEL-ENGIC

280 enrolled

Phase NA Not yet recruiting

Colorectal Neoplasms

NCT07283939 2025-12-16

Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

420 enrolled

Appendiceal Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT07277842 2025-12-11

PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

382 enrolled

Locally Advanced Low Rectal Adenocarcinoma

NCT07271355 2025-12-09

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial

129 enrolled

Appendiceal Neoplasms, Colorectal Neoplasms

NCT06783491 2025-11-24

FOXHIPECT4

1,083 enrolled

Colorectal Neoplasms

NCT07150403 2025-09-08

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

74 enrolled

Colorectal Neoplasms

NCT07155629 2025-09-04

LEFT-PANC

381 enrolled

Pancreatic Cancer Resectable

NCT07085273 2025-07-31

Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer

33 enrolled

Stomach Neoplasms

NCT07062536 2025-07-14

mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line

130 enrolled

Biliary Cancer Metastatic

NCT07028424 2025-07-01

PANORAMIX

206 enrolled

PDAC - Pancreatic Ductal Adenocarcinoma

NCT06899477 2025-03-28

Pre-Operative Treatment in REseCTable COlon CanceR

714 enrolled

Phase 2/3 Not yet recruiting

Colonic Neoplasms

NCT06662877 2024-10-29

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

206 enrolled

Biliary Tract Neoplasms

NCT06648525 2024-10-18

Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC

68 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT06501664 2024-07-15

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

360 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06411171 2024-05-17

Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

36 enrolled

Phase 1/2 Not yet recruiting

Gastroesophageal Junction Cancer

NCT06409637 2024-05-10

FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation

62 enrolled

Liver Neoplasms

NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

Phase 1/2 Not yet recruiting

120 enrolled

Efficacy and Safety

NCT06370754 2024-04-17

FD-IMPACT

117 enrolled

Phase 1/2 Not yet recruiting

Pancreatic Neoplasms

NCT06259058 2024-03-15

Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer

96 enrolled

Pancreatic Neoplasms

NCT06217042 2024-01-22

HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

524 enrolled

Pancreatic Neoplasms

NCT06210360 2024-01-18

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

134 enrolled

Pancreatic Neoplasms

NCT04034173 2019-07-26

Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

120 enrolled